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Abstract
To study the precise role of the neuraminidase (NA), and its stalk region in particular, in the assembly, release, and entry of
influenza virus, we deleted the 20-aa stalk segment from 2009 pandemic H1N1 NA (09N1) and inserted this segment, now
designated 09s60, into the stalk region of a highly pathogenic avian influenza (HPAI) virus H5N1 NA (AH N1). The biological
characterization of these wild-type and mutant NAs was analyzed by pseudotyped particles (pseudoparticles) system.
Compared with the wild-type AH N1, the wild-type 09N1 exhibited higher NA activity and released more pseudoparticles.
Deletion/insertion of the 09s60 segment did not alter this relationship. The infectivity of pseudoparticles harboring NA in
combination with the hemagglutinin from HPAI H5N1 (AH H5) was decreased by insertion of 09s60 into AH N1 and was
increased by deletion of 09s60 from 09N1. When isolated from the wild-type 2009H1N1 virus, 09N1 existed in the forms (in
order of abundance) dimer..tetramer.monomer, but when isolated from pseudoparticles, 09N1 existed in the forms
dimer.monomer...tetramer. After deletion of 09s60, 09N1 existed in the forms monomer...dimer. AH N1 from
pseudoparticles existed in the forms monomer..dimer, but after insertion of 09s60, it existed in the forms
dimer..monomer. Deletion/insertion of 09s60 did not alter the NA glycosylation pattern of 09N1 or AH N1. The 09N1
was more sensitive than the AH N1 to the NA inhibitor oseltamivir, suggesting that the infectivity-enhancing effect of
oseltamivir correlates with robust NA activity.
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Introduction
Influenza A viruses cause seasonal epidemics and occasional
pandemics [1,2,3]. The outbreak of a novel H1N1 influenza strain
became a major global issue in April 2009 and, to date, this virus,
here designated 2009H1N1, has been detected in 214 countries
and has caused 17,919 deaths [4]. In addition, a highly pathogenic
avian influenza (HPAI) H5N1 virus has been circulating in Europe
and Asia for more than a decade and has spread to more than 60
countries; thus far, it has infected 486 humans and killed 287 of
them [5]. Although reports of human-to-human HPAI H5N1
transmission are rare, its high lethality has raised considerable
concern worldwide.
Influenza viruses contain eight negative-sense single-stranded
RNA segments that together encode 11 proteins [2]. Two of these
proteins, hemagglutinin (HA) and neuraminidase (NA), are large
glycoproteins found on viral envelope [1,2,6]. HA mediates
binding of the virus to host cell receptors and promotes entry of
the viral genome into the target cell through membrane fusion,
whereas NA cleaves terminal sialic acids from oligosaccharide
side-chain receptors that bind the mature progeny virus particles,
thereby releasing them from infected cells, and regulates virus
entry [2]. HA and NA are also human antigens; the host immune
responses to these proteins are used to classify influenza A viruses
into 16 HA subtypes and nine NA subtypes (hence the ‘‘H#N#’’
designation for influenza A serotypes) [1,2]. HA is a trimeric, rod-
shaped molecule that is anchored in the viral membrane by its
carboxyl (C)-terminus; cleavage of the HA precursor molecule
(HA0) into two subunits (HA1 and HA2) is required for full activity
[1,2,7,8]. NA is a mushroom-shaped tetramer of monomers that
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transmembrane domain, a stalk, and a globular head [2,9,
10,11]. The evolution of influenza HA and NA proteins has been
monitored closely in recent years and has revealed significant
variation in the NA stalk region [12–14]. Based on their
sequences, NA stalk regions have been divided into six types
[15]. Compared to the A/Gs/Gd/1/96/H5N1-like stalk region,
the A/WSN/33/H1N1-like stalk region has a 16-amino acid (aa)
deletion of residues 57–72, A/Puerto Rico/8/34/H1N1-like has
15-aa deletion of residues 63–77, A/Hong Kong/156/97/H5N1-
like has a 19-aa deletion of residues 54–72, A/chicken/Italy/
1067/99/H7N1-like has 22-aa deletion of residues 54–75, and A/
chicken/Hubei/327/2004/H5N1-like has a 20-aa deletion of
residues 49–68 [15]. The extent of these deletions appears to have
increased gradually; however, the biological impacts of variations
in the NA stalk are not yet clear.
Studies of the A/WSN/33/H1N1 strain have shown that its
biology has not been altered significantly by accumulating deletions
and insertions [11]. However, recent studies have indicated that the
NA stalk plays a critical role in viral replication, virulence,
pathogenesis, and species adaptation [9,15,16]. Our previous
studies showed that the NA activity of A/Ohio/07/2009/H1N1
was much higher than that of HPAI H5N1 (A/Anhui/1/2005) and
that this increased activity is a key reason that the NA inhibitor
oseltamivir enhances the infectivity of 2009H1N1 [17].
In our previous study, a primary sequence alignment revealed a
20-aa (60-bp) deletion in the stalk region of HPAI H5N1 (A/
Anhui/1/2005) NA relative to that of 2009H1N1 NA [17]. Here,
we examined the precise role of NA, and particularly its stalk
region, in influenza A virus assembly, release, and entry, by
deleting the 20-aa segment (residues 49–68) from the stalk region
of 2009H1N1 NA, and inserted this segment, designated 09s60,
into the stalk region of H5N1 NA. We then made HA/NA
pseudoparticles containing all possible combinations of each HA
with each wild-type and mutant NA. The pseudoparticles were
evaluated by transmission electron microscopy, virion quantifica-
tion; hemagglutination, NA, and infectivity assays; and Western
blot analysis of HA and NA expression in pseudoparticles
producer cells and incorporation into pseudoparticles. The effect
of oseltamivir on these pseudoparticles was also assessed.
Materials and Methods
Cell culture
For pseudotyping, A549 targeting cells and 293T human
embryo kidney pesudoparticle producer cells were obtained from
American Type Culture Collection (Manassas, VA) and grown in
Dulbecco’s modified essential medium (DMEM; Invitrogen,
Carlsbad, CA) supplemented with or without 10% fetal bovine
serum.
Construction of NA and HA expression plasmids
The cDNA fragments encoding full-length NA (A/Ohio/07/
2009, the most early released NA sequence of 2009 H1N1 which
without aa difference with that of A/California/05/2009/H1N1
isolate) and HA (A/California/05/2009) proteins from 2009
pandemic H1N1 and HPAI H5N1 (A/Anhui/1/2005) were
cloned into the expression plasmids (Figure 1A) as reported
previously [17–21]. The H5N1-derived HA and NA were
designated AH H5 and AH N1, respectively, and the
2009H1N1-derived HA and NA were designated 09H1 and
09N1, respectively. One of the notable differences between the
H5N1 and 2009H1N1 NA proteins was that the 09N1 contained a
20-aa (60-bp) ‘‘insertion’’ in its stalk region relative to the AH N1
stalk region. This 20-aa segment of 09N1, designated s60 or 09s60,
was deleted from 09N1 to generate 09N1-s60 and inserted into
AH N1 to generate AH N1+09s60. Due to lacking of antibody
against AN NA, a 66His-coding sequence [(ATG)6] was added to
the C-terminal ends of the AH N1 and AH N1+09s60 coding
sequences to facilitate Western blot analysis.
Pseudoparticle production and quantification
As we reported previously [17–21], pseudoparticles were
produced by transfecting 293T cells with four plasmids: an HA
expression plasmid, an NA expression plasmid, a GagPol-encoding
plasmid, and a cytomegalovirus (CMV)–green fluorescent protein
(GFP) reporter plasmid (for details, please see Figure 1A, B, and
C). Eight types of pseudoparticles were made. Those containing
HA and NA from the same virus (e.g., AH H5::AH N1 and
09H1::09N1) were considered ‘‘native,’’ and those containing HA
and NA of different viruses (e.g., AH H5::09N1 and 09H1::AH N1)
were considered ‘‘mismatched’’. A pseudoparticle containing a
mutant NA could be either a ‘‘native mutant’’ (e.g., AH H5::AH
N1+09s60) or a ‘‘mismatched mutant’’ (e.g., AH H5::09N1-s60),
depending on whether the AH and NA came from the same
(native) or different (mismatched) viruses.
At 72 h post-transfection, pseudoparticles were harvested from
the transfected cell culture media by filtration through a 0.45-mm
Durapore polyvinylidene fluoride (PVDF) membrane filter (Milli-
pore Ireland, Cork, Ireland). For quantification, purified pseudo-
particles were treated with 0.24 U/ml DNase and RNase at 37uC
for 1 h to eliminate any contaminating DNA and RNA and then
frozen at –70uC to inactivate the DNase and RNase. The
pseudoparticles were then treated with proteinase K (Qiagen,
Valencia, CA) at 40uC for 30 min to digest the envelope proteins
and release the CMV–GFP RNA. The proteinase K was
inactivated at 100uC for 2 min.
The amount of CMV–GFP RNA in each pseudoparticle was
quantified by real-time quantitative reverse-transcription (qRT)–
PCR using the forward primer 59-CCCGTGAGTCAAACCGC-
TAT-39, the reverse primer 59-GTGATGCGGTTTTGGCA-
GTA-39, and the probe 59-FAM-CCACGCCCATTGATG-
NFQ-39, where FAM is the fluorescent dye 6-carboxy-fluorescein
and NFQ is a non-fluorescent quencher. The assay was carried out
on an ABI 7500 Fast Real-Time PCR System (Applied
Biosystems, Foster City, CA) with a PrimeScript One Step RT–
PCR Kit (Takara, Japan). Pseudoparticles were normalized for
RNA copy number before infectivity, hemagglutination, and NA
activity assays, and Western blot analysis of the HA and NA
expression and incorporation.
Transmission electron microscopy
The supernatant of the medium containing pseudoparticles
were concentrated at 40,000 rpm for 25 min in a Hitachi
centrifuge (Hitachi, Japan). Subsequently, both the original and
concentrated supernatants were negative stained, and the
pseudoparticles were observed using transmission electron micros-
copy (TECNAI 12, FEI, Blackwood, NJ) with an acceleration
voltage of 80 kV.
Infectivity assay
Pseudoparticles were assayed for infectivity as reported
previously [17–21]. Briefly, pseudoparticles (normalized for RNA
copy number) were diluted 1:1 in 100 mL of DMEM. To infect
cells, the cell culture medium was removed and replaced with the
diluted pseudoparticle suspension. The plate was allowed to stand
for 4 h, and the pseudoparticle suspension was removed and
replaced with DMEM supplemented with 10% fetal bovine serum.
NA Characterization
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phosphate-buffered saline (PBS). The number of GFP reporter-
positive cells was determined by fluorescence-activated cell sorting
(BD FACSAria; BD Biosciences, Franklin Lakes, NJ).
We previously reported that oseltamivir inhibits viral NA
activity and pseudoparticle release while boosting viral infectivity
in vitro [17,20]. Here, to examine the relationship between NA
activity and the infectivity-enhancing effect of oseltamivir, we
performed parallel infectivity assays on the pseudoparticle
suspensions in the presence of 0.25 mM oseltamivir.
Hemagglutination assay
The pseudoparticles were assayed for hemagglutination activity.
The normalized pseudoparticle samples were serially diluted 1:2 in
PBS in microplate wells (50 mL/well). Next, 50-mL aliquots of
turkey red blood cells (1% suspension) were added to each well.
Hemagglutination was scored 30 min later.
NA activity assay
The NA activity of the 09N1, 09N1-s60, AH N1, and AH
N1+09s60 proteins was assayed using an NA-Star Influenza
Neuraminidase Inhibitor Resistance Detection Kit (Applied
Biosystems). All reagents were prepared according to the
manufacturer’s instructions. For each sample, normalized pseu-
doparticles were diluted 1:1 in NA-Star Assay buffer, incubated
with 10 mL of NA-Star chemiluminescent substrate for 30 min at
room temperature, and analyzed using a luminometer (2103
Envision Multilabel Reader; Perkin-Elmer, Waltham, MA).
Western blot analysis of HA and NA expression and
incorporation into pseudoparticles
The expression of HA and NA in 293T producer cells was
analyzed after pseudoparticle harvesting. Cells in 6-well plates
were washed twice with PBS to remove residual culture medium
and then lysed in a 500 mL/well of reporter lysis buffer (Promega,
Madison, WI). After centrifugation to remove cell debris, 20 mLo f
each cell lysate sample was mixed with 46 LDS Sample Buffer
(Invitrogen), heated to 100uC for 5 min, and analyzed by Western
blotting as described below.
To evaluate HA and NA incorporation into pseudoparticles and
to assess the possible influence of NA mutations as well as partner
mismatches on HA incorporation, the pseudoparticles were
Figure 1. Diagrams of HA/NA expression plasmids, GagPol-encoding plasmid, and CMV–GFP reporter plasmid, and transmission
electron microscope observation. A. HA/NA expression plasmids, HA/NA encoding sequences were inserted between the CMV promoter and
poly A Tbgh (bovine growth hormone) tail. B. Murine leukemia virus GagPol-encoding plasmid, GagPol-encoding sequence was inserted between the
CMV promoter and the Rabbit beta-globin G ploy A tail. C. CMV–GFP reporter plasmid, the EGFP sequence was inserted into the U3 and U5 sequence
of murine leukemia virus. D. Transmission electron microscopy image of pseudoparticles.
doi:10.1371/journal.pone.0015825.g001
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copies of each pseudoparticle were mixed with 46 LDS Sample
Buffer (Invitrogen), heated to 100uC for 5 min, and analyzed by
Western blotting as described below.
For Western blot analysis, the prepared cell lysate and
pseudoparticle samples (in non-reduced condition) were subjected
to electrophoresis on 12% NuPage gels (Invitrogen). After
electrophoresis, the separated proteins were transferred to PVDF
membranes (Pall Corp., Port Washington, NY) using a semi-dry
transfer method. For HA and NA detection, the membranes were
blocked with skim milk overnight at 4uC. They were then
incubated with a primary antibody against 09H1 (Sino Biological
Inc, Beijing, China), AH H5 (Dr. Mifang Liang), 09N1 (AbMax
Biotechnology Co., Ltd, Beijing, China), or 66His-Tag (mouse
monoclonal antibody from CWBIO, Beijing, China) for 1.5 h at
room temperature. After three washes in PBS, the membranes
were incubated with a biotinylated secondary antibody (Vector
Laboratories, Burlingame, CA) for 20 min at room temperature
and washed three times in PBS. NA and HA were then visualized
using a DAB Substrate Kit (Vector Laboratories).
Data analysis
Differences were evaluated using a two-tailed Fisher’s exact test
(SPSS, release 12.1; SPSS Inc., Chicago, IL). Differences were
considered statistically significant at P,0.05.
Results
Amino acid sequence alignments
We compared the amino acid sequences of the HA proteins
from the 2009 pandemic influenza strain A/California/05/2009/
H1N1 (GenBank #FJ966952) and influenza A/Anhui/1/2005/
H5N1 (#DQ371928). As shown in Figure 2 (upper panel), these
two HA sequences, designated 09H1 and AH H5, respectively,
differ at 207 of 569 residues (36.4%), exhibiting considerable
variation in their glycosylation, receptor binding, and cleavage
sites.
We also compared the sequences of the NA proteins from
influenza A/Ohio/07/2009/H1N1 (#FJ969534) and influenza
A/Anhui/1/2005/H5N1. As shown in Figure 2 (lower panel),
these two NA sequences, designated 09N1 and AH N1,
respectively, differ at 55 of 469 residues (11.7%). In particular,
the 09N1 stalk region contains a 20-aa segment (designated s60 or
09s60; highlighted in yellow) that is not present in AH N1. This
gap in the AH N1 stalk region sequence results in the loss of four
potential glycosylation sites (gray boxes) and a cysteine residue
from AH N1. Of the 29 aas in the transmembrane domains, there
are 8 aas difference (27.5%) which is much higher than the that of
other regions, As previously noted, the 15 charged active site
residues are conserved [18,22,23].
To examine the precise function of the NA stalk region in viral
assembly, entry, and release, we deleted the 20-aa stalk segment
from 09N1 to create 09N1-s60, and we inserted this s60 segment
into AH N1 to create AH N1+09s60.
Transmission electron microscope observation
To verify the pesudoparticles, we observed it using transmission
electron microscopy. The pesudoparticles were visible as a particle
surrounded with HA and NA spikes, which matches the typical
viral morphology of influenza virus (Figure 1D). Meanwhile, no
typical viral morphology of influenza virus was found neither in
the supernatant from naı ¨ve 293T cell nor in the supernatant from
297T cell transfected with a GagPol-encoding plasmid and a
CMV–GFP reporter plasmid but no HA and NA expression
plasmids. Together with the following serial functional assessment
on both HA and NA of pseudoparticles, what we observed is the
functional HA/NA bearing pseudotyped influenza viruses particle.
The pseudoparticle-releasing ability of 09N1 is stronger
than that of AH N1, independent of the stalk region
insertion
By removing terminal sialic acids from the oligosaccharide side
chains to which viral HA binds, NA plays a central role in the
release of the virus from infected cells [2]. To compare the virus-
releasing ability of 09N1 and AH N1, and to examine the role of
the stalk region in this function, we generated eight pseudopar-
ticles by combining each of the two HAs (AH H5 and 09H1) with
each of the four wild-type and mutant NAs (09N1, AH N1, 09N1-
s60, and AH N1+09s60. The number of pseudoparticle RNA
copies produced was determined using real-time qRT-PCR with
primers and a probe targeting the mRNA for the CMV–GFP
reporter gene packaged in the pseudoparticles.
The pseudoparticle copy number did not differ significantly
between AH H5::AH N1 and AH H5::AH N1+09s60 (P=0.062),
AH H5::09N1 and AH H5::09N1-s60 (P=0.129), 09H1::09N1
and 09H1::09N1-s60 (P=0.060), and 09H1::AH N1 and
09H1::AH N1+09s60 (P=0.061; Fig. 3). On the other hand, for
the AH H5-harboring pseudoparticles, approximately twice as
many pseudoparticles were released by 09N1 and 09N1-s60 as by
AH N1 and AH N1+09s60 (P=0.001; Fig. 3, left); similarly, for
09H1-harboring pseudoparticles, more pseudoparticles were
released by 09N1 and 09N1-s60 than by AH N1 and AH
N1+09s60 (P,0.0001; Fig. 3, right). Taken together, these results
show that 09N1 is more effective at pseudoparticle release than
AH N1 and that the 20-aa deletion/insertion in 09N1 and AH N1
does not alter this relationship.
NA activity assessment
Despite the considerable amount of variation known to exist in
the NA stalk region, little research has focused on the effects of
these variations on NA activity. Therefore, we examined the NA
activity of 09N1, 09N1-s60, AH N1, and AH N1+09s60 not only
in their native combinations (AH H5::AH N1, AH H5::AH
N1+09s60, 09H1::09N1, and 09H1::09N1-s60) but also in
mismatched pseudoparticles (09H1::AH N1, 09H1::AH
N1+09s60, AH H5::09N1, and AH H5::09N1-s60). As we
reported previously, the NA activity of 09N1 was much higher
than that of AH N1 (17, 18). When combined with AH H5, AH
N1 and AH N1+09s60 exhibited NA activities of 4231063335
and 4658067054 chemiluminescent units, respectively, indicating
that the 20-aa insertion had little effect on AH N1 activity
(P=0.340). The insertion also had little effect when AH N1 and
AH N1+09s60 were combined with 09H1; the resulting NA
activities were 1677066573 and 1423067636 chemiluminescent
units, respectively (P=0.231). AH N1 and AH N1+09s60
exhibited higher activity in native pseudoparticles (those harboring
AH H5) than in mismatched pseudoparticles (those harboring
09H1; P=0.001; Fig. 4A, left).
When combined with AH H5, 09N1 and 09N1-s60 exhibited
NA activities of 13736206478097 and 16571006598128 chemi-
luminescent units, respectively, indicating that the 20-aa deletion
significantly increased the activity of 09N1 (P=0.011). However,
when combined with 09H1, the deletion in 09N1 did not
significantly alter its activity; in this case, 09N1 and 09N1-s60
had NA activities of 23674706698727 and 25189206619100
chemiluminescent units, respectively (P=0.172). The NA activities
of 09N1 and 09N1-s60 were higher in combination with 09H1
NA Characterization
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higher activity in the native pseudoparticles than in the
mismatched pseudoparticles.
Hemagglutination assays
To examine the influence of the wild-type and mutant NA
proteins on their partner HA proteins, the pseudoparticles were
normalized for RNA copy number and assayed for hemaggluti-
nation activity, as described previously [18,19]. The mean HA
titers were similar for all native, mismatched, and mutant
combinations of AH H5 (AH H5::AH N1, AH H5::AH
N1+09s60, AH H5:09N1, and AH H5:09N1-s60; Fig. 4B, left),
indicating that neither the viral origin of the NA partner nor the
NA deletion/insertion mutation affected the hemagglutination
ability of AH H5. For combinations of 09H1 (09H1::AH N1,
09H1::AH N1+09s60, 09H1::09N1, and 09H1::09N1-s60), the
mean HA titers were somewhat higher with 09N1 and 09N1-s60
than with AH N1 and AH N1+09s60, but neither the deletion in
09N1 nor the insertion into AH N1 caused a significant change in
the hemagglutination titer (Fig. 4B, right).
Infectivity assays
To more closely examine the role of NA, and the NA stalk in
particular, we determined the infectivity of pseudoparticles
Figure 2. Alignment of influenza virus A hemagglutinin (HA; upper) and neuraminidase (NA; lower) sequences to those of the 2009
pandemic H1N1 strain (2009H1N1). Dots indicate residues that are identical to the corresponding residues in 2009H1N1, and dashes indicate
deleted residues. Signal peptides are shown in bold type. Gray boxes indicate potential glycosylation sites, as predicted from the amino acid
sequence. For HA, red residues represent the precursor cleavage site that links the functional HA1 and HA2 domains, and blue residues represent the
binding site for the sialic acid receptor. For NA, conserved active site residues are highlighted in green, and the 20-aa insertion/deletion segment of
interest in the stalk region is highlighted in yellow.
doi:10.1371/journal.pone.0015825.g002
NA Characterization
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and wild-type or mutant NA. The pseudoparticles were normal-
ized to a virus titer of 1610
4 copies per targeting cell before
assaying.
The infectivity of the native wild-type combination AH H5::AH
N1 was 76.0618.6%, a value almost 40 times that of the other
native wild-type combination (09H1::09N1), which had an
infectivity of 1.9561.48% (Fig. 5; blue bars). The infectivity of
the native mutant combination AH H5::AH N1+09s60
(58.4622.3%) was significantly lower than that of the native
wild-type combination AH H5::AH N1 (76.0618.6%; P=0.005),
suggesting that the insertion of s60 into AH N1 reduced the viral
infectivity of the H5N1 pseudoparticle. On the other hand,
deletion of s60 from the 09N1 stalk region did not alter its
infectivity; the wild-type (09H1::09N1; 1.9561.48%) and mutant
(09H1::09N1-s60; 2.7562.38%) native H1N1 pseudoparticles did
not differ significantly in infectivity (P=0.083; Fig. 5).
For the mismatched 09H1 pseudoparticles, the infectivities of
the wild-type (09H1::AH N1; 2.7561.91%) and mutant
(09H1::AH N1+09s60; 4.7063.37%) pseudoparticles were similar
(P=0.323; Fig. 5). In contrast, the mismatched AH H5
pseudoparticles differed in infectivity; that of the mutant (AH
H5::09N1-s60; 11.0565.07%) was significantly higher than that of
the wild-type (AH H5::09N1; 4.0263.18%) pseudoparticle
(P=0.007; Fig. 5). This result indicates that the deletion of s60
from 09N1 increased the viral infectivity of the mismatched AH
H5::09N1 pseudoparticle. The control H5 and H1 pseudoparti-
cles, which were generated without NA, exhibited the lowest
infectivities (1.2260.25 and 0.7560.16%, respectively; Fig. 5).
The robust NA activity of the 2009H1N1 virus is
responsible for the high sensitivity of the virus to
oseltamivir
We previously reported that oseltamivir boosts the infectivity of
the 2009 pandemic H1N1 virus dramatically in vitro and suggested
that its robust NA activity was the major cause of this effect
[17,20]. Here, we examined the effect of oseltamivir on the
infectivity of pseudoparticles containing the eight native and
mismatched combinations of HA and wild-type or mutant NA
(Fig. 5, white bars). Oseltamivir significantly enhanced the
infectivity of all of the pseudoparticles save the mismatched wild-
type 09H1::AH N1, which is barely infectious. Among the native
AH H5-harboring pseudoparticles, the infectivity of AH H5::AH
N1 and AH H5::AH N1+09s60 was high, even in the absence of
oseltamivir, but oseltamivir provided a further boost, suggesting
that the NA activity of AH N1 is lower than that of 09N1, causing
AH N1 to have only a slight effect on HA entry in the presence of
oseltamivir. Oseltamivir boosted the infectivity of the mismatched
AH H5 pseudoparticles AH H5::09N1 and AH H5::09N1-s60 by
15 and 8 times, respectively, suggesting that the higher the NA
activity, the higher the infectivity-enhancing effect of oseltamivir.
Expression of wild-type and mutant NA proteins
The expression of the 09N1, 09N1-s60, AH N1, and AH
N1+09s60 NA proteins in pseudoparticle producer cells was
analyzed by Western blotting using a 2009 pandemic H1N1 wild-
type virus isolate as a control. As shown in Figure 6A, the wild-type
NA from this virus was detected primarily as a ,120-kDa dimer but
also as a tetramer and, in lesser amounts, as a ,60-kDa monomer.
The molecular mass and glycosylation pattern of 09N1 expressed in
pseudoparticle-infected 293T cells appeared identical to those of the
wild-type NA, but the proportion that was tetrameric was smaller.
The 09N1-s60 protein appeared to be a ,50-kDa monomer,
suggesting that the ,10-kDa deletion of s60 abolished NA
oligomerization but did not alter its glycosylation pattern. The
expression efficiency for the 09N1 and 09N1-s60 proteins was very
similar in all pseudotype combinations, suggesting that the s60
deletion in the 09N1 stalk region did not alter its expression.
As shown in Figure 6B, the molecular masses of AH N1 and AH
N1+09s60 expressed in pseudoparticle-infected 293T cells were ,50
and ,60 kDa, as expected. These two proteins had similar
expression efficiencies in all pseudotype combinations, suggesting
that the insertion in the AH N1 stalk region did not alter its
Figure 3. Influence of NAs on viral release. The AH N1, AH N1+09s60, 09N1, and 09N1-s60 were combined with AH H5 or 09H1 HA to generate
eight pseudoparticles, and the release efficiencies of the resulting pseudoparticles were assessed by quantitative PCR (n=4).
doi:10.1371/journal.pone.0015825.g003
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PLoS ONE | www.plosone.org 6 December 2010 | Volume 5 | Issue 12 | e15825Figure 4. NA and hemagglutination activities of pseudoparticles. (A) NA assay. Pseudoparticles were normalized for RNA copy number and
analyzed for NA activity using a chemiluminescent substrate (n=4). (B) Hemagglutination assay. Pseudoparticles were serially diluted 1:2 in a 96-well
plate. Hemagglutination activity is expressed as the mean HA titer (log2 HA units/50 ml) of each pseudoparticle (n=4).
doi:10.1371/journal.pone.0015825.g004
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AH N1+09s60 wasprimarily dimeric.Thus, the s60 insertion favored
dimerization but did not alter the glycosylation pattern.
Expression of HA proteins
To confirm that the HA proteins were expressed efficiently in all
pseudotype combinations, and to assess any possible effects of
mismatched or mutant NAs on HA expression in pseudoparticle
producer cells, we analyzed HA expression using Western blotting.
Cells infected with any of the pseudotype combinations expressed
AH H5 with a glycosylation pattern and a molecular mass similar
to those of HA from purified, inactivated wild-type H5N1 virus
(Fig. 7A, left). Furthermore, AH H5 was expressed in similar
amounts in all combinations, suggesting that neither the viral
origin of the NA partner (native or mismatched) nor the s60
insertion/deletion affected its expression.
Like AH H5, 09H1 was expressed with a glycosylation pattern
and a molecular mass similar to those of HA from purified,
inactivated wild-type pandemic H5N1 virus in all combinations,
and the viral origin of the NA and the s60 insertion/deletion did
not affect its expression (Fig. 7B, left).
Evaluation of HA and NA incorporation into
pseudoparticles
To evaluate the incorporation of HA and NA into the various
pseudoparticles, the levels of expression of HA and NA in
pseudoparticle batches of 1 million were analyzed by Western
blotting.
The AH H5 protein was expressed at similar levels in all
pseudotype combinations, and its molecular weight and a
glycosylation pattern in all combinations were similar to those of
purified wild-type HPAI H5N1 HA (Fig. 7A, right). Similarly,
HA0 of 09H1 was expressed at similar levels in all pseudotype
combinations and with a molecular weight and a glycosylation
pattern similar to those of HA from wild-type 2009 pandemic
H1N1 (Fig. 7B, right). Notably, HA2 of the pseudoparticles was a
bit light than that of wild-type 2009 pandemic H1N1, this may due
to difference of the glyscosylation efficiency in variant generating
approaches, wild type was inoculated in egg, while, pseudoparti-
cles were produced in 293T cells. Together with the transmission
electron microscopy observation, our data suggest that the AH H5
and 09H1 HA proteins are incorporated with similar efficiency
into all pseudotype combinations and that the s60 insertion/
deletion does not affect this efficiency.
As shown in Figure 6A, the molecular mass of the 09N1 NA
protein in pseudoparticles harboring 09H1 or AH H5 was
identical to that of the NA from wild-type 2009 pandemic
H1N1 virus; the monomer and dimer molecular masses were ,60
and ,120 kDa, respectively. The molecular mass of the 09N1-s60
NA protein in pseudoparticles harboring 09H1 or AH H5 was
,50 kDa. The 09N1 and 09N1-s60 proteins exhibited similar
incorporation efficiencies with 09H1 and AH H5, suggesting that
the incorporation of 09N1 was unaffected by the s60 deletion in its
stalk region. Similarly, when expressed with 09H1 and AH H5,
the molecular masses of AH N1 and AH N1+09s60 were ,50 and
,60 kDa, as expected (Fig. 6B). These proteins exhibited similar
incorporation efficiencies in AH H5- and 09H1-containing
pseudoparticles, suggesting that the incorporation of AH N1 NA
was unaffected by the s60 insertion.
Notably, the NA proteins lacking s60, the 20-aa stalk segment (AH
N1 and 09N1-s60), produced almost no dimers, whereas the NA
proteins containing s60 (09N1 and AH N1+09s60) existed primarily as
dimers; thus, the 20-aa segment appears to be the critical domain for
dimer formation and does not seem to affect glycosylation (Fig. 6B).
Discussion
In this report, we focused on the NA enzymes of two influenza
A virus strains that have had catastrophic effects, HPAI H5N1 and
Figure 5. Infectivity of normalized pseudoparticles. Infectivity is presented as the mean 6 SD percentage of infected cells (n=4). Blue bars,
infectivity of pseudoparticles comprising native combinations of HA and NA (09H1::09N1 and AH H5::AH N1); gray bars, infectivity of mismatched
pseudoparticles; white bars, infectivity of pseudoparticles in the presence of oseltamivir.
doi:10.1371/journal.pone.0015825.g005
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to swine, and then became the human pandemic strain 2009H1N1
[17–21,24]. H5N1 jumped to humans directly from birds [25].
The NAs of both of these viruses display human host adaptations,
but of the two, 09N1 is more robust and is thus more efficient at
viral release. During the 2009H1N1 entry stage, 09N1 might be a
powerful ‘‘block’’ against viral entry, thus making the virus
sensitive to oseltamivir. Although many virologists believe that NA
is tetrameric [1,2,9,10,26], we found that the 09N1 protein of the
wild-type virus was primarily dimeric, although some of it was
tetrameric form, and a much smaller amount was monomeric
western blot analysis. Interestingly, although 09N1 in pseudopar-
ticles was also primarily dimeric, a substantial fraction of it was
monomeric, and very little was tetrameric western blot analysis.
Like the AH N1 NA protein, the 09N1-s60 NA protein, which
lacks a 20-aa segment (residues 49–68; designated s60) of the 09N1
stalk region, was primarily monomeric, with a small amount of the
dimeric form. When the s60 segment of 09N1 was inserted into the
AH N1 stalk region, the resulting AH N1+09s60 protein was
primarily dimeric, with some of the monomeric form also present.
Thus, the stalk region is critical for dimer formation, which may
occur via oxidation of Cys49, and the dimer is the major functional
Figure 6. Western blot analysis of expression of NA in pseudoparticle producer 293 cells and NA incorporation into
pseudoparticles. (A) Pseudoparticles and their producer 293T cell lysates were analyzed for 09N1 and 09N1-s60 expression. Wild-type H1N1
virus A/California/7/2009 (300 ng) was used as a positive control. Mock, normal 293T cell lysate; pps, pseudoparticles. (B) Pseudoparticles and their
producer 293T cell lysates were analyzed for AH N1 and AH N1+09s60 expression. Mock, normal 293T cell lysate; pps, pseudoparticles.
doi:10.1371/journal.pone.0015825.g006
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presence of as many as five potential glycosylation sites, including
the four sites in the 20-aa stalk region.
Of the 29 aas in the NA transmembrane domains, there are 8
aas difference (27.5%) which is much higher than the that of other
regions, although reports indicated that the transmembrane
domain of NA was critical in apical transport [27,28], as far as
we know, no report showed that the transmembrane domain was
critical for pseudoparticle’s budding. At the budding stage,
pseudoparticles were secreted by the gag-pol protein derived from
murine leukemia virus, the NA could only help pseudoparticle
release by cleaving terminal sialic acids from oligosaccharide side-
chain receptors that bind the HA. The more activity of NA, the
more pseudoparticles released. Of the NA activity, 09 NA is almost
100 times higher than that of AH NA, the extreme high NA
activity of 2009 pandemic H1N1 NA was confirmed by our
previous reports [17,18]. Together with our NA incorporation
analysis, the NA activity is determined by the character of each
NA, particular the ectodomain not the transmembrane domain.
Comparison of all of the native and mismatched pseudoparticles
showed that those harboring AH H5 had a much higher infectivity
than those harboring 09H1. This finding suggests that the HPAI
Figure 7. Western blot analysis of expression of HA in pseudoparticle producer 293 cells and HA incorporation into
pseudoparticles. (A) Pseudoparticles and their producer 293T cell lysates were analyzed for AH H5 expression. Wild-type H5N1 virus A/
Vietnam/1194/2005 (300 ng) was used as a positive control. (B) Pseudoparticles and their producer 293T cell lysates were analyzed for 09H1
expression. Wild-type H1N1 virus A/California/7/2009 (300 ng) was used as a positive control.
doi:10.1371/journal.pone.0015825.g007
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underlie the dire clinical outcomes of H5N1-infected patients. Of
the AH H5-harboring pseudoparticles, higher infectivity was
observed for AH H5::AH N1 than for AH H5::AH N1+09s60,
and higher infectivity was observed for AH H5::09N1-s60 than for
AH H5::09N1, suggesting that AH H5 partners more effectively
with NA proteins that have a short stalk or that exist as monomers.
Of the lower infectivity of all pseudoparticles harboring 09HA, the
diversity in glycosylation might be a reason since we observed that
HA2 of our pseudoparticles was poorly glycosylated (Figure 7B
right). We did not observe any influence of the NA stalk on the
infectivity of 09H1-harboring pseudoparticles, but we cannot
discount the possibility that any such influence might have been
masked by the lower infectivity of 09H1.
When we compared the NA activities of all eight pseudoparticle
combinations of AH H5 and 09H1 with 09N1, 09N1-s60, AH N1,
and AH N1+09s60, we found that the s60 insertion or deletion did
not appear to affect NA activity except when AH H5 was
combined with 09N1. Because of this confusion, we doubled the
methodology; the NA-Star NA Inhibitor Resistance Detection Kit
is extremely sensitive and hence lacks the desired reproducibility
and specificity.
Oseltamivir is a NA inhibitor designed to bind to the putative
NA tetramer [10]. However, our current data demonstrate that
the NA of the wild-type 2009 pandemic H1N1 is primarily dimeric
and that it exists in both dimeric and monomeric forms in
pseudoparticles. This finding, in conjunction with our previous
finding that NA dramatically inhibits NA activity [17], casts doubt
upon the accepted pharmacologic mechanism of action of
oseltamivir. We previously noted that oseltamivir boosts the
infectivity of influenza virus [17]; the present comparison of NA
activities in pseudoparticles pairing AH H5 and 09H1 partnered
with native and mismatched NA proteins shows clearly that the
infectivity-enhancing effect of oseltamivir correlates positively with
the NA activity. Therefore, we feel we must again raise an alarm
concerning the use of oseltamivir to treat influenza A in clinical
practice: when the patient’s lung has a high viral load, oseltamivir
administration might enhance the infectivity of the virus,
particularly if the virus has a high NA activity to begin with.
The resulting robust pulmonary immune response could result in
unexpected lung failure.
Retrovirus-based influenza HA/NA pseudoparticle systems
have been demonstrated to accurately represent the biology of
the corresponding wild-type viruses [17–21,29,30]. For research
on HPAI viruses, the use of pseudoparticle systems eliminates not
only routine biosafety issues but also the possibility of production
of a manmade, highly pathogenic virus. Pseudoparticles contain-
ing only HA and NA provide a convenient model for research on
HA/NA matching patterns, viral release, viral entry, neutralizing
antibodies, and many other biological features involving HA and
NA. Although this system cannot completely represent the entire
virus generated by reverse genetics, it has provided us with a safe
and convenient platform for our HA/NA studies.
Due to the lacking of antibody against AH NA, we added a 6 x
His-encoding sequence to the C-terminal ends of the AH NA and
AH N1+09s60 coding sequence to facilitate Western blot analysis.
We have assessed any possible influence of His tag on NA’s
function, there was no difference in NA activity and cooperation
with HA between the pseudoparticles harboring NAs with or
without His tag (data not showed).
The HAs of HPAI viruses have multiple basic amino acids at
their cleavage sites (RERRRKKR) and are cleaved by ubiquitous
proteases in a wide range of organs, resulting in lethal systemic
infection [1]. We observed that pseudoparticles harboring AH H5
were more infective than those harboring 09H1, but whether the
presence of the HPAI HA cleavage site enhances the infectivity of
HPAI H5N1 viruses is unknown. We are currently performing
experiments to address this issue.
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